Galectin Therapeutics (NASDAQ:GALT) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Wednesday, October 31st.
Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Galectin Therapeutics in a report on Thursday, August 16th. BidaskClub upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $7.58.
Shares of GALT opened at $4.74 on Wednesday. Galectin Therapeutics has a 52-week low of $1.28 and a 52-week high of $9.49.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Analysts anticipate that Galectin Therapeutics will post -0.44 EPS for the current year.
In related news, Director Gilbert S. Omenn sold 11,000 shares of the company’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $6.03, for a total value of $66,330.00. Following the completion of the transaction, the director now owns 56,561 shares of the company’s stock, valued at approximately $341,062.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Marc Rubin sold 58,100 shares of the business’s stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $6.08, for a total transaction of $353,248.00. Following the completion of the sale, the director now owns 84,581 shares in the company, valued at approximately $514,252.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 100,370 shares of company stock worth $614,487. Insiders own 38.80% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. D.A. Davidson & CO. grew its stake in Galectin Therapeutics by 5.0% in the 3rd quarter. D.A. Davidson & CO. now owns 689,278 shares of the company’s stock worth $4,143,000 after acquiring an additional 32,751 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Galectin Therapeutics by 2.3% during the third quarter. BlackRock Inc. now owns 601,657 shares of the company’s stock valued at $3,616,000 after purchasing an additional 13,349 shares in the last quarter. First Foundation Advisors bought a new position in shares of Galectin Therapeutics during the third quarter valued at approximately $1,477,000. Millennium Management LLC bought a new position in shares of Galectin Therapeutics during the first quarter valued at approximately $454,000. Finally, Monashee Investment Management LLC bought a new position in shares of Galectin Therapeutics during the third quarter valued at approximately $391,000. 13.73% of the stock is currently owned by institutional investors.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.
Further Reading: What does RSI mean?
To view ValuEngine’s full report, visit ValuEngine’s official website.